This case illustrates resistance in T. vaginalis organisms. Among Administration of a combination of oral (2.5 g/d) and intravagicases of trichomoniasis that fail to respond to treatment, clinicians nal (0.5 g at bedtime) metronidazole for 20 days with oral protend to attribute the treatment failure to poor compliance or to chlorperazine caused vomiting and failed to eradicate the infection. reinfection. As is true for any antimicrobial treatment, resistant Treatment with oral furazolidone, 300-400 mg q.i.d. for 7 days, strains should be considered in cases of persistent infection. Estiwas initiated. The patient developed nausea and brown-colored mates of the prevalence of infection due to metronidazole-resistant urine but was able to complete the treatment course, which resulted T. vaginalis range from marginal (one in 50-75 cases) to high in minimal symptomatic improvement. Wet mount preparations (one in 2,000-3,000 cases) [3] . The case we have described demand cultures of vaginal secretions continued to be positive for onstrates that high doses of tinidazole may be an option for patients trichomonads. Subsequently, she received a vaginal preparation who have infections due to resistant T. vaginalis, even in instances containing 100 mg of furazolidone in 5 g of 3% nonoxynol-9 one of in vitro resistance to the agent. High doses tinidazole therapy to three times daily for 7 days. She noted clinical improvement that were well tolerated in this case. There were fewer side effects persisted for ú1 month after treatment. Her symptoms eventually than associated with metronidazole therapy. The organisms were returned, and trichomonads were again noted in her vaginal secresusceptible to furazolidone. However, oral treatment with furazolitions. There was no interim sexual activity.
done was ineffective, whereas a vaginal preparation containing furazolidone in nonoxynol-9 was associated with impressive, albeit short-lived, symptomatic improvement.
Staphylococcus epidermidis Endocarditis Treated with RP 59500 (Quinapristin/Dalfopristin)
Staphylococcus epidermidis is a common cause of prosthetic valve endocarditis (PVE). Treatment for this condition consists of combination antibiotic therapy including vancomycin, rifampin, and gentamicin. We describe a patient who had a severe allergic response to vancomycin during therapy for PVE due to methicillinresistant Staphylococcus epidermidis (MRSE).
A 44-year-old male with a history of St. Jude mitral-valve replacement 6 months earlier presented with cough, fever, and dyspnea. Physical examination revealed only a systolic murmur. A transesophageal echocardiogram (TEE) revealed a mitral annular abscess, multiple vegetations, and instability of the prosthetic valve (figure 1). Three sets of blood cultures yielded MRSE (bioMérieux Vitek, Hazelwood, MO). The patient underwent mitral-valve re- Figure 1 . Large mitral annular abscess, with multiple moderate-toplacement with reconstruction of the mitral annulus. After an unlarge sized vegetations attached to an unstable prosthetic valve with complicated postoperative course, he was discharged with continpartial suture dehiscence in a patient with Staphylococcus epidermidis ued vancomycin, rifampin, and gentamicin therapy.
endocarditis. LA Å left atrium; LV Å left ventricle; MV Å mitral One week after discharge, the patient developed fever (temperavalve; V Å vegetation; and A Å annular abscess. ture, to 102ЊF). Findings on physical examination were unremarkable. Blood cultures were negative. The fever continued, and a maculopapular rash developed despite discontinuation of rifampin therapy. A repeated TEE showed normal prosthetic function. Van- Teicoplanin, an investigational glycopeptide (not approved by comycin therapy was discontinued. The patient was rechallenged the U.S. Food and Drug Administration) with activity against with vancomycin with premedication; this was followed by fever, gram-positive bacteria [2] has been effective for treatment of streppruritus, tongue swelling, and worsening rash with conjunctival tococcal and staphylococcal endocarditis [3] . Cross-reactivity may involvement. Findings on histopathologic evaluation of a skin bioccur in those patients with vancomycin hypersensitivity who are opsy specimen were consistent with drug eruption. Therapy with treated with teicoplanin [4] . In addition, teicoplanin, which could RP 59500 (quinapristin/dalfopristin; Synercid; Rhôue-Poulenc be obtained previously for compassionate use in the United States, Rorer, Collegeville, PA) was initiated at a dose of 7.5 mg/kg q8h.
has not been available since 1995. Despite symptoms including myalgias, arthralgias, and fatigue, the RP 59500 is a combination of two semisynthetic derivatives of patient completed a 6-week course. Cultures of blood obtained pristinamycin: quinapristin and dalfopristin [5] . In combination, after completion of therapy were sterile. An echocardiogram obquinapristin/dalfopristin, exerts a synergistic antibacterial effect tained 12 weeks after the cessation of therapy showed a normal that is not influenced by most forms of bacterial resistance [6]. prosthetic valve. The patient remains well after 12 months.
This investigational streptogramin is active against a spectrum of Adverse reactions to vancomycin therapy are common but usugram-positive bacteria, including methicillin-susceptible and methally mild (flushing, pruritus, and hypotension) and preventable.
icillin-resistant staphylococci, streptococci, and enterococci; its acSevere reactions to vancomycin are rare. Fever and rashes (ranging tivity is bactericidal against all but enterococci. The mechanism from a pruritic maculopapular rash to toxic epidermal necrolysis) of action involves binding to the 50s bacterial ribosome, resulting have been reported [1] . Therapeutic options for these patients are in a stable complex that irreversibly inhibits bacterial protein synlimited.
thesis. There is no apparent synergy with aminoglycosides. RP 59500 has been effective in animal models for the treatment of endocarditis, showing homogenous distribution throughout experimental vegetations [7] . In a rabbit fibrin clot model, RP 59500
